Share Price and Basic Stock Data
Last Updated: December 9, 2025, 10:45 pm
| PEG Ratio | -5.85 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dhampur Bio Organics Ltd operates within the sugar industry, an essential sector in India with a significant impact on the economy. As of the latest financial data, the company reported a market capitalization of ₹509 Cr and a share price of ₹76.6. Over the past few years, revenue trends have shown fluctuations, with sales standing at ₹2,408 Cr in FY 2023, a notable increase from ₹1,564 Cr in FY 2022. However, the subsequent fiscal year (FY 2024) saw a decline, with sales dropping to ₹1,864 Cr. The trailing twelve months (TTM) figure reflects a slight recovery at ₹1,920 Cr, suggesting some stabilization. The quarterly sales data indicates a peak of ₹803 Cr in March 2023, followed by a drop in subsequent quarters, which raises questions about seasonal demand and operational efficiency. This volatility in revenue could be a concern for investors looking for consistency.
Profitability and Efficiency Metrics
Profitability metrics for Dhampur Bio Organics Ltd present a mixed picture. The company reported a negative net profit of ₹7 Cr in FY 2025, a stark contrast to the ₹111 Cr net profit in FY 2023. Operating profit margins (OPM) have also seen volatility, peaking at 14% in March 2023 but subsequently showing signs of deterioration, with an OPM of just 5% in TTM. The interest coverage ratio (ICR) of 2.06x indicates that while the company can meet its interest obligations, it is not in a robust position. The return on equity (ROE) stands at a low 1.56%, suggesting that shareholders may not be seeing adequate returns on their investments, further compounded by a high P/E ratio of 297, which implies that the stock might be overvalued given its current earnings performance. These profitability challenges underscore the need for operational improvements and strategic management to enhance efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Dhampur Bio Organics Ltd reveals a mixed bag of strengths and weaknesses. Total borrowings amount to ₹562 Cr, against reserves of ₹895 Cr, indicating a leverage ratio that is manageable but still concerning given the company’s profitability struggles. The debt-to-equity ratio of 1.14x suggests that the company is somewhat reliant on debt for financing, which can be risky in a volatile market. The current ratio of 1.14x shows that the company can cover its short-term liabilities, but the quick ratio of 0.12x raises red flags about liquidity. The book value per share has remained relatively stable, standing at ₹152.39, and the price-to-book value ratio of 0.43x indicates that the stock is trading at a significant discount to its book value. This could attract value investors, but the underlying performance metrics need to improve for the company to leverage this potential.
Shareholding Pattern and Investor Confidence
Investor confidence in Dhampur Bio Organics Ltd appears to be waning, reflected in its shareholding pattern. Promoters hold a substantial 50.65% stake, but foreign institutional investors (FIIs) have significantly reduced their holdings from 6.63% in December 2022 to just 0.35% by September 2025. Domestic institutional investors (DIIs) have similarly remained low, holding only 0.45%. Public shareholding, however, is relatively high at 47.67%, indicating that retail investor interest still exists. The number of shareholders has also declined to 48,055, which may hint at a growing discontent among investors regarding the company’s operational performance and profitability. This shift in shareholding dynamics could affect the company’s market perception and its ability to attract future investments or strategic partnerships.
Outlook, Risks, and Final Insight
The outlook for Dhampur Bio Organics Ltd is complex, with several risks and opportunities on the horizon. The company needs to address its profitability issues, particularly given the declining net profit and fluctuating OPM. Operational efficiency must be improved to stabilize revenues and enhance margins. The heavy reliance on debt presents another risk, especially in an environment where interest rates may rise. However, the low price-to-book ratio could be enticing for value investors, provided the company can turn its performance around. Investors should be cautious, weighing the potential for recovery against the backdrop of operational challenges and market volatility. The path forward will largely depend on management’s ability to execute a robust strategy that focuses on improving efficiency, reducing debt, and ultimately restoring investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dhampur Bio Organics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri Sugars Ltd | 80.7 Cr. | 10.9 | 17.4/7.02 | 288 | 16.8 | 0.00 % | 36.6 % | % | 10.0 |
| Dhampure Speciality Sugars Ltd | 86.3 Cr. | 98.8 | 141/82.0 | 21.9 | 45.3 | 0.00 % | 11.6 % | 8.88 % | 10.0 |
| Dhampur Bio Organics Ltd | 519 Cr. | 78.0 | 134/57.3 | 304 | 145 | 1.60 % | 3.97 % | 1.56 % | 10.0 |
| DCM Shriram Industries Ltd | 1,474 Cr. | 170 | 214/142 | 24.2 | 105 | 1.18 % | 13.7 % | 11.8 % | 2.00 |
| Davangere Sugar Company Ltd | 555 Cr. | 3.86 | 12.4/3.03 | 43.9 | 3.52 | 0.00 % | 6.70 % | 3.17 % | 1.00 |
| Industry Average | 1,719.78 Cr | 257.39 | 44.33 | 225.56 | 0.71% | 8.62% | 7.89% | 6.37 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 496 | 515 | 594 | 803 | 583 | 538 | 280 | 463 | 467 | 466 | 464 | 464 | 526 |
| Expenses | 464 | 493 | 559 | 687 | 543 | 519 | 284 | 382 | 434 | 476 | 448 | 369 | 524 |
| Operating Profit | 32 | 22 | 34 | 116 | 41 | 19 | -4 | 81 | 33 | -10 | 16 | 96 | 1 |
| OPM % | 6% | 4% | 6% | 14% | 7% | 4% | -2% | 18% | 7% | -2% | 3% | 21% | 0% |
| Other Income | 3 | 6 | 1 | 2 | 2 | 1 | 16 | 5 | 1 | 1 | -1 | 1 | 2 |
| Interest | 14 | 9 | 5 | 13 | 13 | 9 | 6 | 18 | 21 | 16 | 10 | 20 | 22 |
| Depreciation | 8 | 9 | 10 | 13 | 11 | 10 | 14 | 14 | 12 | 11 | 15 | 16 | 14 |
| Profit before tax | 12 | 11 | 20 | 92 | 18 | 0 | -8 | 54 | 1 | -35 | -10 | 61 | -33 |
| Tax % | 29% | 28% | 26% | 13% | 32% | 88% | -28% | 28% | 83% | -34% | -32% | 26% | -33% |
| Net Profit | 8 | 8 | 15 | 80 | 13 | 0 | -6 | 39 | 0 | -23 | -7 | 45 | -22 |
| EPS in Rs | 1.24 | 1.16 | 2.26 | 12.08 | 1.91 | 0.01 | -0.85 | 5.94 | 0.02 | -3.52 | -1.03 | 6.75 | -3.31 |
Last Updated: August 19, 2025, 8:10 pm
Below is a detailed analysis of the quarterly data for Dhampur Bio Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 526.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 526.00 Cr., marking an increase of 62.00 Cr..
- For Expenses, as of Jun 2025, the value is 524.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 369.00 Cr. (Mar 2025) to 524.00 Cr., marking an increase of 155.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 95.00 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 0.00%, marking a decrease of 21.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.00 Cr. (Mar 2025) to 22.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 61.00 Cr. (Mar 2025) to -33.00 Cr., marking a decrease of 94.00 Cr..
- For Tax %, as of Jun 2025, the value is -33.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to -33.00%, marking a decrease of 59.00%.
- For Net Profit, as of Jun 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Mar 2025) to -22.00 Cr., marking a decrease of 67.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.31. The value appears to be declining and may need further review. It has decreased from 6.75 (Mar 2025) to -3.31, marking a decrease of 10.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:31 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,564 | 2,408 | 1,864 | 1,862 | 1,920 |
| Expenses | 0 | 1,381 | 2,203 | 1,724 | 1,727 | 1,817 |
| Operating Profit | -0 | 183 | 205 | 140 | 135 | 103 |
| OPM % | 12% | 8% | 8% | 7% | 5% | |
| Other Income | 0 | 8 | 11 | 20 | 2 | 3 |
| Interest | 0 | 30 | 41 | 45 | 67 | 68 |
| Depreciation | 0 | 31 | 41 | 49 | 54 | 56 |
| Profit before tax | -0 | 129 | 135 | 65 | 16 | -18 |
| Tax % | 0% | 21% | 18% | 29% | 6% | |
| Net Profit | -0 | 102 | 111 | 46 | 15 | -7 |
| EPS in Rs | 16.74 | 7.00 | 2.21 | -1.11 | ||
| Dividend Payout % | 0% | 0% | 21% | 36% | 56% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 8.82% | -58.56% | -67.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | -67.38% | -8.83% |
Dhampur Bio Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -46% |
| TTM: | -117% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:44 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 66 | 66 | 66 | 66 | 66 | 66 |
| Reserves | 709 | 812 | 922 | 945 | 945 | 895 |
| Borrowings | 403 | 835 | 810 | 1,057 | 1,162 | 562 |
| Other Liabilities | 373 | 287 | 278 | 244 | 223 | 121 |
| Total Liabilities | 1,551 | 2,000 | 2,077 | 2,313 | 2,398 | 1,645 |
| Fixed Assets | 631 | 690 | 909 | 1,036 | 1,076 | 1,136 |
| CWIP | 7 | 78 | 36 | 13 | 79 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 913 | 1,232 | 1,132 | 1,263 | 1,242 | 498 |
| Total Assets | 1,551 | 2,000 | 2,077 | 2,313 | 2,398 | 1,645 |
Below is a detailed analysis of the balance sheet data for Dhampur Bio Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 66.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 66.00 Cr..
- For Reserves, as of Sep 2025, the value is 895.00 Cr.. The value appears to be declining and may need further review. It has decreased from 945.00 Cr. (Mar 2025) to 895.00 Cr., marking a decrease of 50.00 Cr..
- For Borrowings, as of Sep 2025, the value is 562.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,162.00 Cr. (Mar 2025) to 562.00 Cr., marking a decrease of 600.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 121.00 Cr.. The value appears to be improving (decreasing). It has decreased from 223.00 Cr. (Mar 2025) to 121.00 Cr., marking a decrease of 102.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,645.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,398.00 Cr. (Mar 2025) to 1,645.00 Cr., marking a decrease of 753.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,136.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,076.00 Cr. (Mar 2025) to 1,136.00 Cr., marking an increase of 60.00 Cr..
- For CWIP, as of Sep 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 79.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 71.00 Cr..
- For Investments, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 498.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,242.00 Cr. (Mar 2025) to 498.00 Cr., marking a decrease of 744.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,645.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,398.00 Cr. (Mar 2025) to 1,645.00 Cr., marking a decrease of 753.00 Cr..
Notably, the Reserves (895.00 Cr.) exceed the Borrowings (562.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | -403.00 | -652.00 | -605.00 | 139.00 | 134.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 25 | 23 | 17 | 11 | |
| Inventory Days | 341 | 163 | 288 | 288 | |
| Days Payable | 54 | 33 | 37 | 29 | |
| Cash Conversion Cycle | 312 | 154 | 269 | 270 | |
| Working Capital Days | 56 | 24 | 33 | 21 | |
| ROCE % | 11% | 10% | 5% | 4% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Diluted EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Cash EPS (Rs.) | 10.33 | 14.46 | 22.84 | 20.06 | 0.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Revenue From Operations / Share (Rs.) | 280.39 | 280.83 | 362.63 | 232.10 | 0.00 |
| PBDIT / Share (Rs.) | 20.86 | 24.15 | 32.56 | 28.68 | 0.00 |
| PBIT / Share (Rs.) | 12.74 | 16.69 | 26.45 | 23.96 | 0.00 |
| PBT / Share (Rs.) | 2.37 | 9.86 | 20.30 | 19.43 | 0.00 |
| Net Profit / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| NP After MI And SOA / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| PBDIT Margin (%) | 7.43 | 8.59 | 8.97 | 12.35 | 0.00 |
| PBIT Margin (%) | 4.54 | 5.94 | 7.29 | 10.32 | 0.00 |
| PBT Margin (%) | 0.84 | 3.51 | 5.59 | 8.36 | 0.00 |
| Net Profit Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| NP After MI And SOA Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| Return on Networth / Equity (%) | 1.45 | 4.59 | 11.23 | 11.61 | 0.00 |
| Return on Capital Employeed (%) | 6.42 | 8.78 | 14.41 | 15.23 | 0.00 |
| Return On Assets (%) | 0.61 | 2.01 | 5.34 | 5.09 | 0.00 |
| Long Term Debt / Equity (X) | 0.23 | 0.17 | 0.17 | 0.11 | 0.12 |
| Total Debt / Equity (X) | 1.14 | 1.03 | 0.81 | 0.93 | 0.50 |
| Asset Turnover Ratio (%) | 0.79 | 0.84 | 1.18 | 0.86 | 0.00 |
| Current Ratio (X) | 1.14 | 1.19 | 1.31 | 1.28 | 1.46 |
| Quick Ratio (X) | 0.12 | 0.16 | 0.35 | 0.17 | 0.29 |
| Inventory Turnover Ratio (X) | 1.71 | 1.69 | 1.69 | 1.62 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 113.00 | 49.96 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 24.20 | 24.20 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -13.00 | 50.04 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 75.80 | 75.80 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.06 | 3.54 | 5.29 | 6.32 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 1.25 | 2.03 | 3.72 | 4.38 | 0.00 |
| Enterprise Value (Cr.) | 1553.77 | 1776.49 | 1647.22 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.83 | 0.95 | 0.68 | 0.00 | 0.00 |
| EV / EBITDA (X) | 11.22 | 11.08 | 7.62 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| Retention Ratios (%) | -13.00 | 50.03 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.43 | 0.75 | 0.96 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| EarningsYield | 0.03 | 0.06 | 0.11 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dhampur Bio Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 14.46 (Mar 24) to 10.33, marking a decrease of 4.13.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 280.39. It has decreased from 280.83 (Mar 24) to 280.39, marking a decrease of 0.44.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.86. This value is within the healthy range. It has decreased from 24.15 (Mar 24) to 20.86, marking a decrease of 3.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.74. This value is within the healthy range. It has decreased from 16.69 (Mar 24) to 12.74, marking a decrease of 3.95.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.37. This value is within the healthy range. It has decreased from 9.86 (Mar 24) to 2.37, marking a decrease of 7.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 10. It has decreased from 8.59 (Mar 24) to 7.43, marking a decrease of 1.16.
- For PBIT Margin (%), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 10. It has decreased from 5.94 (Mar 24) to 4.54, marking a decrease of 1.40.
- For PBT Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 10. It has decreased from 3.51 (Mar 24) to 0.84, marking a decrease of 2.67.
- For Net Profit Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 8. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has decreased from 4.59 (Mar 24) to 1.45, marking a decrease of 3.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 8.78 (Mar 24) to 6.42, marking a decrease of 2.36.
- For Return On Assets (%), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 2.01 (Mar 24) to 0.61, marking a decrease of 1.40.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.23, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.14. This value exceeds the healthy maximum of 1. It has increased from 1.03 (Mar 24) to 1.14, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.84 (Mar 24) to 0.79, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has decreased from 1.19 (Mar 24) to 1.14, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.16 (Mar 24) to 0.12, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 4. It has increased from 1.69 (Mar 24) to 1.71, marking an increase of 0.02.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 113.00. This value exceeds the healthy maximum of 50. It has increased from 49.96 (Mar 24) to 113.00, marking an increase of 63.04.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 24.20. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 24.20.
- For Earning Retention Ratio (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 40. It has decreased from 50.04 (Mar 24) to -13.00, marking a decrease of 63.04.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 75.80. This value exceeds the healthy maximum of 70. There is no change compared to the previous period (Mar 24) which recorded 75.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.06. This value is below the healthy minimum of 3. It has decreased from 3.54 (Mar 24) to 2.06, marking a decrease of 1.48.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.25, marking a decrease of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,553.77. It has decreased from 1,776.49 (Mar 24) to 1,553.77, marking a decrease of 222.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 24) to 0.83, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 11.22. This value is within the healthy range. It has increased from 11.08 (Mar 24) to 11.22, marking an increase of 0.14.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For Retention Ratios (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 30. It has decreased from 50.03 (Mar 24) to -13.00, marking a decrease of 63.03.
- For Price / BV (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.43, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dhampur Bio Organics Ltd:
- Net Profit Margin: 0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.42% (Industry Average ROCE: 8.62%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 7.89%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.25
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 304 (Industry average Stock P/E: 44.33)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.14
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.78%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Sugar | Sugar Mill Compound, Village & Post - Asmoli, Sambhal Dist. Uttar Pradesh 244304 | investors@dhampur.com http://www.dhampur.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Kumar Goel | Chairman |
| Mr. Ashwani Kumar Gupta | Vice Chairman |
| Mr. Gautam Goel | Managing Director & CEO |
| Mr. Sandeep Kumar | Whole Time Director |
| Mrs. Bindu Vashist Goel | Non Executive Director |
| Mrs. Ruchika Amrish Mehra Kothari | Independent Director |
| Mr. Vishal Saluja | Independent Director |
| Mr. Samir Thukral | Independent Director |
| Mr. Kishor Shah | Independent Director |
FAQ
What is the intrinsic value of Dhampur Bio Organics Ltd?
Dhampur Bio Organics Ltd's intrinsic value (as of 10 December 2025) is 558.92 which is 616.56% higher the current market price of 78.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 519 Cr. market cap, FY2025-2026 high/low of 134/57.3, reserves of ₹895 Cr, and liabilities of 1,645 Cr.
What is the Market Cap of Dhampur Bio Organics Ltd?
The Market Cap of Dhampur Bio Organics Ltd is 519 Cr..
What is the current Stock Price of Dhampur Bio Organics Ltd as on 10 December 2025?
The current stock price of Dhampur Bio Organics Ltd as on 10 December 2025 is 78.0.
What is the High / Low of Dhampur Bio Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dhampur Bio Organics Ltd stocks is 134/57.3.
What is the Stock P/E of Dhampur Bio Organics Ltd?
The Stock P/E of Dhampur Bio Organics Ltd is 304.
What is the Book Value of Dhampur Bio Organics Ltd?
The Book Value of Dhampur Bio Organics Ltd is 145.
What is the Dividend Yield of Dhampur Bio Organics Ltd?
The Dividend Yield of Dhampur Bio Organics Ltd is 1.60 %.
What is the ROCE of Dhampur Bio Organics Ltd?
The ROCE of Dhampur Bio Organics Ltd is 3.97 %.
What is the ROE of Dhampur Bio Organics Ltd?
The ROE of Dhampur Bio Organics Ltd is 1.56 %.
What is the Face Value of Dhampur Bio Organics Ltd?
The Face Value of Dhampur Bio Organics Ltd is 10.0.